ranscend Biologics is highlighting recently published research examining platelet-rich plasma (PRP) preparations in patients with knee osteoarthritis.
The study, conducted at Fondazione Policlinico Universitario Agostino Gemelli IRCCS in Rome, Italy, evaluated the use of neutrophil-depleted platelet-rich plasma in individuals diagnosed with knee osteoarthritis.
The research is titled:
“High Dose Neutrophil-Depleted Platelet-Rich Plasma Therapy for Knee Osteoarthritis: A Retrospective Study.”
The investigators analyzed clinical records from 212 patients diagnosed with Kellgren-Lawrence grade 1–3 knee osteoarthritis who received PRP preparations as part of physician-directed care.
This publication contributes to a growing body of scientific literature exploring platelet-rich plasma preparations within musculoskeletal research.
Platelet-Rich Plasma in Musculoskeletal Research
Platelet-rich plasma is an autologous biologic preparation derived from a patient’s own blood. PRP is produced using centrifugation systems designed to concentrate platelets and plasma fractions.
PRP preparation systems typically process a blood sample by separating blood components into layers, including:
red blood cells
platelet-poor plasma
platelet-rich plasma
The platelet-rich fraction contains concentrated platelets and platelet-derived signaling proteins that are commonly studied in regenerative medicine research.
Researchers continue to investigate how platelet concentration, leukocyte levels, and preparation protocols influence the composition of platelet-rich plasma.
Overview of the Study
In this retrospective analysis, investigators reviewed outcomes among 212 patients with knee osteoarthritis who received PRP preparations prepared using a neutrophil-depleted platelet-rich plasma protocol.
Patients in the study received three PRP injections according to the treatment protocol used by the treating physicians.
The study monitored several clinical assessment measures over a 12-month observation period.
According to the authors, many patients in the study demonstrated measurable changes in reported outcome scores during follow-up evaluations.
As with many studies examining PRP, investigators noted that additional prospective research and standardized preparation protocols are needed to further clarify findings.
Why PRP Preparation Characteristics Matter
One of the important variables discussed in PRP research is how platelet-rich plasma is prepared.
Different PRP preparation systems may produce samples that vary in:
platelet concentration
leukocyte levels
red blood cell content
platelet-derived protein profiles
These variables may influence the biological characteristics of the resulting PRP preparation.
Because of this variability, researchers frequently emphasize the importance of standardized preparation methods and reproducible platelet concentrations when evaluating PRP in clinical research.
PRP Preparation Systems Used in Clinical Research
PRP preparation systems such as Tropocells® are designed to process whole blood using controlled centrifugation and gel-separation technology.
These systems are intended to assist clinicians in isolating platelet-rich plasma while minimizing red blood cell contamination during preparation.
Preparation systems may differ in:
centrifugation protocols
platelet recovery rates
leukocyte content
workflow design
Comparative studies help researchers evaluate how these variables affect the composition of PRP preparations.
Ongoing Research in Orthobiologics
Interest in orthobiologic technologies continues to expand across musculoskeletal medicine.
Researchers are actively studying:
platelet-rich plasma preparations
platelet concentration levels
leukocyte-reduced PRP preparations
standardization of PRP preparation protocols
The findings from these studies help clinicians and researchers better understand how platelet-rich plasma preparations vary across different systems and preparation methods.
Access the Study
The full research article can be accessed through the following link:
Regulatory Notice
Tropocells® systems are intended for the preparation of autologous platelet-rich plasma. Clinical use of PRP is determined by the treating physician. Statements regarding clinical applications reflect published scientific literature and are not intended to imply FDA-cleared indications.
Reference
High Dose Neutrophil-Depleted Platelet-Rich Plasma Therapy for Knee Osteoarthritis: A Retrospective Study.
Preprints.org.